Antimalarial
Antimalarial drugs have the obvious connotation of therapeutic utility against malaria, but certain drugs with activity against malaria also are immunomodulators used in rheumatology.
In general use, the term applies specifically to synthetic analogs of quinine, rather than antibiotics or other drugs with activity against malarial parasites and other protozoa. The major drugs of this type are:
- 4-aminoquinolone derivatives
- 9-aminoacridine derivatives
Treatment of malaria
For malaria, chloroquine is the most important drug; quinacrine is no longer in commercial tablet production but, as a third-line agent, is available from compounding pharmacies.
Rheumatology
These are examples of disease-modifying antirheumatic drugs, which directly affect the disease process rather than simply providing pain control. Their most important use was in systemic lupus erythematosis, [1] but they also have applicability to rheumatoid arthritis, palindromic arthritis and psoriatic arthritis. In a 1998 study comparing chloroquine and hydrochloroquine, [2] hydroxychloroquine was less toxic but less effective than chloroquine, but there were no firm recommendations of one over the other. Hydroxychloroquine is considerably more expensive.
Side effects
Damage to the eyes are the greatest concerns. These drugs may deposit in the melanin of the pigmented epithelial layer of the retina. Since early damage is often reversible, thorough opthalmologic examination is advised every 6 to 12 months.
References
- ↑ Hochberg MC et al., ed. (2004), Practical Rheumatology (Third Edition ed.), Mosby, ISBN 0323029396, pp. 440-442}}
- ↑ J Antonio Aviña-Zubieta et al. (1998), "Long term effectiveness of antimalarial drugs in rheumatic diseases", Ann Rheum Dis 57: 582-587, DOI:10.1136/ard.57.10.582